Mode
Text Size
Log in / Sign up

Panic disorder symptoms decreased during guideline-based pharmacotherapy in small observational cohortPanic disorder symptoms improved during six months of standard medication treatment

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note symptom improvement in PD with pharmacotherapy, but evidence is observational and limited.

In a retrospective observational cohort study, 41 adults with DSM-5-diagnosed panic disorder receiving guideline-based pharmacotherapy were followed for six months. The study examined changes in symptom severity and the association with autistic traits, which were measured only at the six-month follow-up. No comparator group was specified, and the specific pharmacotherapy regimen was not detailed.

The primary finding was a significant decrease in both Panic Disorder Severity Scale (PDSS) total scores and PDSS agoraphobia scores over the six-month treatment period (p < 0.001 for both). The study did not report absolute score changes, effect sizes, or the proportion of patients achieving specific response criteria. Safety and tolerability data, including adverse events and discontinuation rates, were not reported.

Key limitations include the retrospective design, which precludes establishing causation, and the measurement of autistic traits only after the treatment period, making it difficult to assess their baseline influence on treatment response. The small sample size of 41 patients and lack of a control group further limit generalizability. For clinicians, this study provides preliminary observational evidence that panic and agoraphobia symptoms may decrease over time with guideline-based pharmacotherapy, but the evidence strength is low due to the study design.

Researchers looked at how adults with panic disorder fared while taking standard medications for six months. The study included 41 people who were already diagnosed with panic disorder and receiving guideline-based drug treatment. The goal was to see how their symptoms changed over time.

Over the six-month period, the participants' overall panic symptoms and their specific fears related to open spaces or crowds (agoraphobia) both decreased significantly. The study measured these changes using standard rating scales. The researchers noted these improvements were statistically clear.

It's important to understand this was a small, observational study that looked back at existing data. The study design means we can see that symptom improvement happened alongside treatment, but we cannot say for certain that the medications caused the improvement. The researchers also measured autistic traits only at the end of the six months, which makes it hard to understand their role. Readers should see this as early information from a small group, not as definitive proof of how well these medications work for everyone.

What this means for you:
A small study found panic symptoms improved during standard medication treatment, but more research is needed to confirm the results.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Panic disorder (PD) exhibits marked clinical heterogeneity, and individual differences in autistic traits may contribute to variability in symptom severity and treatment course. This study examined whether autistic traits are associated with panic severity and agoraphobic avoidance during pharmacological treatment. In this retrospective observational study, 41 adults with DSM-5-diagnosed PD receiving guideline-based pharmacotherapy were followed over six months. Symptom trajectories were assessed using the Panic Disorder Severity Scale (PDSS) at baseline, one month, and six months, while autistic traits were measured using the Autism Spectrum Quotient (AQ) at the six-month visit. Linear mixed-effects models and repeated-measures ANCOVA examined associations between autistic traits and symptom burden while adjusting for age and sex. PDSS total and agoraphobia scores declined significantly over time (p
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.